Magnetic resonance imaging and 11C-N-methylspiperone/positron emission tomography studies in a patient with the interval form of carbon monoxide poisoning.
Magnetic resonance (MR) and (11)C-N-methylspiperone ((11)C-NMSP)/positron emission tomography (PET) imagings were repeatedly performed in a 50-year-old man with the interval form of carbon monoxide (CO) poisoning. In MR images obtained when delayed neuropsychiatric symptoms developed (two months after poisoning), the inner segments of the bilateral globus pallidus appeared as high signal intensities in the T1-weighted and low signal intensities in the T2-weighted images, suggesting prior focal hemorrhage in these areas. A PET study with (11)C-NMSP performed at that time showed an increase in dopamine D2 receptor binding in the caudate and putamen. Treatment with bromocriptine was very effective and five months after the poisoning, MR and (11)C-NMSP/PET images showed improvement, concomitantly with the disappearance of the neuropsychiatric symptoms.
Yoshii
F
F
Department of Neurology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Kozuma
R
R
Takahashi
W
W
Haida
M
M
Takagi
S
S
Shinohara
Y
Y
D001479:Basal Ganglia / Q000737:chemistry / Q000473:pathology; D001971:Bromocriptine / Q000627:therapeutic use; D002249:Carbon Monoxide Poisoning / Q000150:complications / Q000378:metabolism / Q000473:pathology*; D002250:Carbon Radioisotopes; D002421:Caudate Nucleus / Q000378:metabolism / Q000473:pathology; D002543:Cerebral Hemorrhage / Q000175:diagnosis / Q000209:etiology / Q000473:pathology; D003131:Combined Modality Therapy; D003289:Convalescence; D018492:Dopamine Antagonists / Q000627:therapeutic use; D065127:Dopamine D2 Receptor Antagonists; D005917:Globus Pallidus / Q000737:chemistry / Q000473:pathology*; D006801:Humans; D006931:Hyperbaric Oxygenation; D007980:Levodopa / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D009419:Nerve Tissue Proteins / Q000032:analysis* / Q000037:antagonists & inhibitors; D010302:Parkinson Disease, Secondary / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D011597:Psychomotor Performance; D011699:Putamen / Q000737:chemistry / Q000473:pathology; D017448:Receptors, Dopamine D2 / Q000032:analysis*; D013134:Spiperone / Q000031:analogs & derivatives*; D014055:Tomography, Emission-Computed
D002250:Carbon Radioisotopes; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D009419:Nerve Tissue Proteins; D017448:Receptors, Dopamine D2; D001971:Bromocriptine; D007980:Levodopa; D013134:Spiperone; C039167:3-N-methylspiperone